Lei Jiang1, Dongsheng Fei1, Rui Gong1, Wei Yang1, Wei Yu1, Shangha Pan2, Mingran Zhao3, Mingyan Zhao4. 1. Department of ICU, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang province, China. 2. The Key Hepatosplenic Surgery Laboratory, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China. 3. Department of Pediatrics, Children's Hospital of Harbin City, Harbin, China. 4. Department of ICU, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang province, China. mingyan1970@126.com.
Abstract
OBJECTIVE: Accumulated studies suggest that exogenously administered carbon monoxide is beneficial for the resolution of acute lung inflammation. The present study aimed to examine the effects and the underlying mechanisms of CORM-2 on thioredoxin-interacting protein (TXNIP)/NLRP3 inflammasome pathway in lipopolysaccharide (LPS)-induced acute lung injury (ALI). METHODS: ALI was intratracheally induced by LPS in C57BL6 mice. CORM-2 or iCORM-2 (30mg/kg i.p.) was administered immediately before LPS instillation. 6 h later, lung bronchoalveolar lavage (BAL) fluids were acquired for IL-18, IL-1β, and cell measurement, and lung issues were collected for histologic examination, wet/dry weight ratio, and determination of TXNIP/NLRP3 inflammasome expression, NLRP3 inflammasome and NF-ΚB activity, and reactive oxygen species (ROS) production. RESULTS: LPS triggered significant lung edema, lung injury, and leukocyte infiltration, and elevated the levels of IL-1β and IL-18 in lung BAL fluids. CORM-2 pretreatment resulted in a marked amelioration of lung injury and reduced IL-1β and IL-18 secretion in BAL fluids. In lung tissues; CORM-2 down-regulated mRNA and protein level of TXNIP, NLRP3, ASC, and caspase-1. Furthermore, CORM-2 reduced ROS production, inhibited NLRP3 inflammasome and NF-κB activity, and interaction of TXNIP-NLRP3. However, no significant differences were detected between the LPS and iCORM-2 (an inactive variant of CORM-2) group. CONCLUSION: CORM-2 suppresses TXNIP/NLRP3 inflammasome pathway and protects against LPS-induced lung injury.
OBJECTIVE: Accumulated studies suggest that exogenously administered carbon monoxide is beneficial for the resolution of acute lung inflammation. The present study aimed to examine the effects and the underlying mechanisms of CORM-2 on thioredoxin-interacting protein (TXNIP)/NLRP3 inflammasome pathway in lipopolysaccharide (LPS)-induced acute lung injury (ALI). METHODS: ALI was intratracheally induced by LPS in C57BL6 mice. CORM-2 or iCORM-2 (30mg/kg i.p.) was administered immediately before LPS instillation. 6 h later, lung bronchoalveolar lavage (BAL) fluids were acquired for IL-18, IL-1β, and cell measurement, and lung issues were collected for histologic examination, wet/dry weight ratio, and determination of TXNIP/NLRP3 inflammasome expression, NLRP3 inflammasome and NF-ΚB activity, and reactive oxygen species (ROS) production. RESULTS:LPS triggered significant lung edema, lung injury, and leukocyte infiltration, and elevated the levels of IL-1β and IL-18 in lung BAL fluids. CORM-2 pretreatment resulted in a marked amelioration of lung injury and reduced IL-1β and IL-18 secretion in BAL fluids. In lung tissues; CORM-2 down-regulated mRNA and protein level of TXNIP, NLRP3, ASC, and caspase-1. Furthermore, CORM-2 reduced ROS production, inhibited NLRP3 inflammasome and NF-κB activity, and interaction of TXNIP-NLRP3. However, no significant differences were detected between the LPS and iCORM-2 (an inactive variant of CORM-2) group. CONCLUSION: CORM-2 suppresses TXNIP/NLRP3 inflammasome pathway and protects against LPS-induced lung injury.
Authors: Maria T Kuipers; Hamid Aslami; John R Janczy; Koenraad F van der Sluijs; Alexander P J Vlaar; Esther K Wolthuis; Goda Choi; Joris J T H Roelofs; Richard A Flavell; Fayyaz S Sutterwala; Paul Bresser; Jaklien C Leemans; Tom van der Poll; Marcus J Schultz; Catharina W Wieland Journal: Anesthesiology Date: 2012-05 Impact factor: 7.892
Authors: Naoko Kamo; Bibo Ke; Amir A Ghaffari; Xiu-da Shen; Ronald W Busuttil; Genhong Cheng; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2013-05-15 Impact factor: 17.425
Authors: Edward Gomperts; John D Belcher; Leo E Otterbein; Thomas D Coates; John Wood; Brett E Skolnick; Howard Levy; Gregory M Vercellotti Journal: Am J Hematol Date: 2017-04-29 Impact factor: 10.047
Authors: Agnieszka M Jurga; Anna Piotrowska; Wioletta Makuch; Barbara Przewlocka; Joanna Mika Journal: Front Pharmacol Date: 2017-02-16 Impact factor: 5.810